{"title":"Advances and Future Prospects of Lipid-Based Nanocarriers in Targeted Cancer Therapy: A Comprehensive Review.","authors":"Suraj Mandal","doi":"10.2174/0115680096351325250412164059","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Targeted cancer therapy has significantly transformed the field of oncology by improving treatment precision and reducing the occurrence of unintended side effects. Lipid-based nanocarriers have become a viable platform for delivering chemothera-peutic drugs due to their biocompatibility, flexibility, and ability to be functionalised.</p><p><strong>Aim and objectives: </strong>The objective of this research is to investigate the present tactics and future prospects of lipid-based nanocarriers in the field of targeted cancer treatment. The goals include the examination of recent progress in the development of lipid nanocarriers, evaluating their effectiveness in clinical uses, and pinpointing opportunities for enhancement and novelty.</p><p><strong>Material and method: </strong>An extensive literature analysis was performed, including examining current research on the use of lipid-based nanocarriers in cancer treatment. An analysis was conducted on data pertaining to nanocarrier formulations, targeting mechanisms, treatment results, and clinical trials in order to detect trends and new technologies.</p><p><strong>Results: </strong>Recent progress in lipid-based nanocarriers, including liposomes, solid lipid nano-particles, and nanoemulsions, has shown enhanced drug delivery and decreased toxicity. Targeting methods, such as the utilisation of ligand-receptor interactions and stimuli-responsive systems, have significantly improved the precision and effectiveness of therapeu-tics.</p><p><strong>Conclusion: </strong>Lipid-based nanocarriers have great potential for advancing targeted cancer treatment in the future. Although there has been significant progress, it is essential to con-tinue developing formulation processes and targeting tactics to overcome existing con-straints and improve clinical results. Ongoing cooperation across several fields of study will be crucial in effectively applying these nanotechnologies from the laboratory to practical use in healthcare.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current cancer drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115680096351325250412164059","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Targeted cancer therapy has significantly transformed the field of oncology by improving treatment precision and reducing the occurrence of unintended side effects. Lipid-based nanocarriers have become a viable platform for delivering chemothera-peutic drugs due to their biocompatibility, flexibility, and ability to be functionalised.
Aim and objectives: The objective of this research is to investigate the present tactics and future prospects of lipid-based nanocarriers in the field of targeted cancer treatment. The goals include the examination of recent progress in the development of lipid nanocarriers, evaluating their effectiveness in clinical uses, and pinpointing opportunities for enhancement and novelty.
Material and method: An extensive literature analysis was performed, including examining current research on the use of lipid-based nanocarriers in cancer treatment. An analysis was conducted on data pertaining to nanocarrier formulations, targeting mechanisms, treatment results, and clinical trials in order to detect trends and new technologies.
Results: Recent progress in lipid-based nanocarriers, including liposomes, solid lipid nano-particles, and nanoemulsions, has shown enhanced drug delivery and decreased toxicity. Targeting methods, such as the utilisation of ligand-receptor interactions and stimuli-responsive systems, have significantly improved the precision and effectiveness of therapeu-tics.
Conclusion: Lipid-based nanocarriers have great potential for advancing targeted cancer treatment in the future. Although there has been significant progress, it is essential to con-tinue developing formulation processes and targeting tactics to overcome existing con-straints and improve clinical results. Ongoing cooperation across several fields of study will be crucial in effectively applying these nanotechnologies from the laboratory to practical use in healthcare.
期刊介绍：
Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes.
Current Cancer Drug Targets publishes original research articles, letters, reviews / mini-reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer.
As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
